Solid Bioscience Gene Therapy UpdateAugust 19, 2019 8:49 am
Alex’s Wish have received a positive update from Solid Bioscience on their gene therapy trial called IGNITE DMD which Alex’s Wish invested in. They announced that the second patient has been dosed in the higher dose cohort of the IGNITE DMD Phase I/II clinical trial of SGT-001, which is four times higher than our starting dose.
Solid has also made amendments to the IGNITE DMD clinical study. One change includes adding an upper weight limit although Solid remains committed to dosing larger patients in the future. Another amendment is the removal of the matched patient control arm for the rest of the second cohort. They believe these changes will speed up the path to obtaining IGNITE DMD clinical trial results. As always, Solid understands the urgency in advancing meaningful therapies responsibly with the goal of impacting the broadest population of patients affected by Duchenne.
Solid continues to anticipate providing a data update from the IGNITE DMD clinical trial later this year and we look forward to sharing all progress you, our supporters.